CAI (CAI) Stock Forecast & Price Target

Caris Life Sciences is viewed positively because its core molecular profiling franchise is compounding quickly, with Q3'26 revenue of $275M, core molecular profiling revenue of $263M, and 61.5k volumes all beating expectations while adjusted EBITDA rose to $44M and gross margin held at 66%. Its outlook is further strengthened by durable pricing power from MI Cancer Seek’s $8,455 Medicare rate, expanding payer coverage, a 325-person sales force, and a raised 2026 revenue guide to $1.04B-$1.05B on expected +20% clinical volume growth. Beyond the core business, the launch of Caris Detect and the planned December rollout of Confirm MRD expand addressable markets, while the $769M cash balance and a $1.1B Genentech collaboration support continued investment and optionality.

Caris Life Sciences is facing a cautious fundamental setup because slower-than-expected revenue contribution from Caris Assure could limit near-term growth while competition remains intense from large, established laboratories across tissue, blood, MRD, and early-detection testing. Its newer programs also carry meaningful execution risk, with reimbursement uncertainty, pricing and contracting challenges, and commercialization risk for both the blood-based therapy selection test and planned launches in MRD and early cancer detection. Valuation volatility across precision oncology, potential litigation, and modest balance sheet risk add further downside pressure, especially as Detect is priced at $3,500 per test on a self-pay basis with no insurance coverage or FDA clearance.